Arteris/$AIP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arteris
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum its revenue from Asia Pacific.
- Ticker
- $AIP
- Sector
- Software & Cloud Services
- Primary listing
- NASDAQ
- Employees
- 373
- Headquarters
- Campbell, United States
- Website
- www.arteris.com
Arteris Metrics
BasicAdvanced
$949M
-
-$0.90
1.97
-
Price and volume
Market cap
$949M
Beta
1.97
52-week high
$50.26
52-week low
$12.06
Average daily volume
659K
Financial strength
Current ratio
1.345
Quick ratio
1.261
Long term debt to equity
0.086
Total debt to equity
0.139
Interest coverage (TTM)
-182.47%
Profitability
EBITDA (TTM)
-32.594
Gross margin (TTM)
86.91%
Net profit margin (TTM)
-44.83%
Operating margin (TTM)
-40.62%
Effective tax rate (TTM)
4.96%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-14.07%
Return on equity (TTM)
-153.20%
Valuation
Price to revenue (TTM)
9.546
Price to book
14.39
Price to tangible book (TTM)
74.51
Price to free cash flow (TTM)
409.393
Free cash flow yield (TTM)
0.24%
Free cash flow per share (TTM)
0.047
Growth
Revenue change (TTM)
41.03%
Earnings per share change (TTM)
7.75%
3-year revenue growth (CAGR)
21.09%
3-year earnings per share growth (CAGR)
-2.32%
What the Analysts think about Arteris
Analyst ratings (Buy, Hold, Sell) for Arteris stock.
Analyst projections of the future price of Arteris stock.
Bulls say / Bears say
Q3 momentum is strong: revenue rose 48% to $25.8 million, trailing-twelve-month royalties grew 71%, and ACV plus royalties increased 39%. Arteris also raised its 2026 revenue outlook. (Arteris)
Customer adoption is broadening, with Arteris surpassing 1,000 confirmed design starts and reporting expanded deals with a major hyperscaler, two leading semiconductor firms and an automotive OEM. More repeat and multi-product use could deepen customer relationships. (Arteris)
Chiplets offer a potential growth lever: management says they account for about 10% of design starts today and could reach 30%–35% in two to three years. Arteris says these projects tend to carry higher average selling prices, and it has expanded its multi-die product range. (The Motley Fool, Arteris)
Arteris remains loss-making on a GAAP basis: its Q3 operating loss widened to $11.3 million from $8.7 million a year earlier, and its net loss was $11.2 million. Rapid sales growth has therefore not yet translated into GAAP profitability. (Arteris)
Cash generation is uneven: Q3 free cash flow was negative $2.1 million and year-to-date free cash flow was negative $0.9 million. The full-year positive $5–$9 million forecast now depends on a substantial Q4 improvement. (Arteris, The Motley Fool)
Near-term growth could cool: Q4 revenue guidance of $25.7–$26.7 million is broadly flat against Q3's $25.8 million, while the ACV-plus-royalties outlook starts below Q3's $103.8 million. The low ends leave little room for further growth next quarter. (Arteris)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Arteris Financial Performance
Revenues and expenses
Arteris Earnings Performance
Company profitability
Upcoming events
No upcoming events
Arteris News
AllArticlesVideos
Funds containing Arteris
Fund name | Fund size | $AIP weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.02% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.